1.Expression of Myc-R9-EGFP fusion protein and validation of its transduction activity.
Huiqun YIN ; Yunhai ZHANG ; Heng WANG ; Xueping SUN ; Ya LIN ; Hongguo CAO ; Xiaorong ZHANG
Journal of Biomedical Engineering 2012;29(3):508-513
To construct, express, purify and identify the Myc-R9-EGFP fusion protein and validate its transduction activity in the cultured porcine embryo fibroblasts. cDNA of pig c-Myc gene was amplified by RT-PCR with specific primers of 9 arginine (R9) from the primordial genital ridges and inserted into prokaryotic expression vector pET-28a-EGFP. After DNA sequencing confirmation, the recombinant plasmid was then transformed into BL21 (Escherichia coli) strain. After IPTG induction, the target fusion protein was efficiently induced to express, successfully purified by Novagen His-Bind kit, identified by SDS-PAGE and Western blotting. Finally, its high transduction activity in the porcine embryo fibroblasts was validated. The purified Myc-R9-EGFP fusion protein and the validation of its transduction activity in fibroblasts have provided an experimental foundation for further studies on the biological characterization of Myc protein, and soundly facilitated the further study of establishing pig induced pluripotent stem cells by recombinant protein.
Animals
;
Arginine
;
genetics
;
metabolism
;
Cell Line
;
Cell Membrane Permeability
;
drug effects
;
Escherichia coli
;
genetics
;
metabolism
;
Fibroblasts
;
cytology
;
metabolism
;
Genetic Vectors
;
genetics
;
Green Fluorescent Proteins
;
genetics
;
metabolism
;
Proto-Oncogene Proteins c-myc
;
genetics
;
metabolism
;
Recombinant Fusion Proteins
;
genetics
;
metabolism
;
pharmacokinetics
;
Swine
2. Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients
Aining SUN ; Xiaopeng TIAN ; Xiangshan CAO ; Jian OUYANG ; Jian GU ; Kailin XU ; Kang YU ; Qingshu ZENG ; Zimin SUN ; Guoan CHEN ; Sujun GAO ; Jin ZHOU ; Jinghua WANG ; Linhua YANG ; Jianmin LUO ; Mei ZHANG ; Xinhong GUO ; Xiaomin WANG ; Xi ZHANG ; Keqian SHI ; Hui SUN ; Xinmin DING ; Jianda HU ; Ruiji ZHENG ; Hongguo ZHAO ; Ming HOU ; Xin WANG ; Fangping CHEN ; Yan ZHU ; Hong LIU ; Dongping HUANG ; Aijun LIAO ; Liangming MA ; Liping SU ; Lin LIU ; Zeping ZHOU ; Xiaobing HUANG ; Xuemei SUN ; Depei WU
Chinese Journal of Hematology 2017;38(12):1017-1023
Objective:
To investigate the efficacy and safety of IA regimen which contains idarubicin (IDA) 8 mg/m2, 10 mg/m2 or 12 mg/m2 as induction chemotherapy for adult patients with de-novo acute myeloid leukemia (AML) .
Methods:
A total of 1 215 newly diagnosed adult AML patients, ranging from May 2011 to March 2015 in the First Affiliated Hospital of Soochow University and other 36 clinical blood centers in China were enrolled in the multicenter, single-blind, non-randomized, clinical controlled study. To compare the response rate of complete remission (CR) , adverse events between different dose idarubicin combined with cytarabine (100 mg/m2) as induction chemotherapy in newly diagnosed patients of adult AML.
Results:
Of 1 207 evaluable AML patients were assigned to this analysis of CR rate. The CR rates of IDA 8 mg/m2 group, IDA 10 mg/m2 group and IDA 12 mg/m2 group were 73.6% (215/292) , 84.1% (662/787) and 86.7% (111/128) , respectively (